


first risk-based screening for cervical cancer in Europe



RISCC is a multidisciplinary consortium of key researchers in Human Papillomavirus (HPV) and cervical cancer prevention.

#1

This is the first newsletter of the RISCC project, a European Commission funded project to facilitate the implementation of the first risk-based screening programs in Europe.

If you want to receive this newsletter directly into your email inbox every 3-4 months, use the following link to subscribe to it:

www.riscc-h2020.eu/newsletter/



You will always have the option to unsubscribe if you no longer wish to receive it.

In this issue you will find:

■ **What is the RISCC project?**

■ **News and events**

■ **Publications so far**



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847845.

WHAT IS THE RISCC PROJECT

BACKGROUND and RATIONALE

There is a pressing need to change the current cervical cancer screening in Europe:

HPV vaccinated women are reaching screening age, and their precancer risk differs greatly from unvaccinated women with the same test result.

Improved technologies should be applied on the screening program with limited consequences for clinical management.

In risk-based screening programs, clinical management is provided according to each woman's individual risk of precancer based on her screening history, vaccination status and other risk factors. It prioritizes women at high risk, reduces distress and overtreatment for women at lower risk (by avoiding unnecessary tests) and reduces costs and burden: in Europe, investing 2€ per woman annually can cut the current incidence of cervical cancer in half. Prioritizing an expedite diagnosis and treatment of women at higher risk (reduced burden by means of a more effective screening).


PROJECT OBJECTIVES



To develop and evaluate the first risk-based screening program for cervical cancer in Europe.



To provide open-source tools to facilitate its implementation.



ORGANIZATION and METHODOLOGY

RISCC consists of 11 partners divided among 7 work packages that will:

Define **risk profiles** based on screening history, vaccination status and other risk factors such as age.

Provide **screening recommendations** for different levels of precancer risk.


Assess the **cost-effectiveness** of risk-based cervical cancer screening programs.

Conduct a **pilot** risk-based screening program for cervical cancer in Europe.

Develop and provide **open-source IT tools** to facilitate clinical management.

Offer free online **training** for personnel involved in screening programs.

REQUIRED BASELINE DATA



RISK-BASED CERVICAL CANCER SCREENING PROGRAM



IMPLEMENTATION TOOLS

For more information visit our website: www.riscc-h2020.eu.

NEWS AND EVENTS

RISCC consortium meeting (December 9th 2020)

Due to the COVID-19 pandemic, the second RISCC consortium meeting was held online. It was a very productive and inspiring meeting in which all members evaluated together the progress of the project. The status of each work package was presented and the work plan was updated accordingly to achieve the planned goals for the project.



Follow us on Twitter!

The Twitter account for the project [@RISCC_H2020](https://twitter.com/RISCC_H2020) is already active. In it we will post information about the project and relevant information on cervical cancer prevention!

Join us to get the latest information and news on the project!



[@RISCC_H2020](https://twitter.com/RISCC_H2020)

PUBLICATIONS SO FAR

Weyers, S et al. "Cervical Cancer Prevention in Transgender Men: A Review." BJOG, 2020.

Kyrgiou, M., et al. "Cervical Screening: ESGO-EFC Position Paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC)." BJC, 2020.

Latsuzbaia, A., et al. "Characterization and Diversity of 243 Complete Human Papillomavirus Genomes in Cervical Swabs Using Next Generation Sequencing." Viruses, 2020.

Ejegod, D.M., et al. "Clinical Validation of the Cobas 4800 HPV Assay Using Cervical Samples in SurePath Medium under the VALGENT4 Framework." JCV 2020.

Poljak, M., et al. "Commercially Available Molecular Tests for Human Papillomaviruses: A Global Overview." CMI, 2020.

Peeters, E., et al. "Efficacy of Strategies to Increase Participation in Cervical Cancer Screening: GPs Offering Self-Sampling Kits for HPV Testing versus Recommendations to Have a Pap Smear Taken - A Randomised Controlled Trial." PVR, 2020.

Inturrisi, F., et al. "Estimating the Direct Effect of Human Papillomavirus Vaccination on the Lifetime Risk of Screen-Detected Cervical Precancer." IJC, 2020.

Ciavattini, A., et al. "European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) Joint Considerations about Human Papillomavirus (HPV) Vaccination, Screening Programs, Colposcopy, and Surgery during and after the COVID-19 Pandemic." IJGC, 2020.

Bray, F., et al. "Geographic and Temporal Variations in the Incidence of Vulvar and Vaginal Cancers." IJC, 2020.

Inturrisi, F., et al. "Risk of Cervical Intraepithelial Neoplasia Grade 3 or Worse in HPV-Positive Women with Normal Cytology and Five-Year Type Concordance: A Randomized Comparison." CEBP, 2020.

Tagliabue, M., et al. "Role of Human Papillomavirus Infection in Head and Neck Cancer in Italy: The HPV-AHEAD Study." Cancers, 2020.

Arbyn, M., et al. "Tackling Cervical Cancer in Europe amidst the COVID-19 Pandemic." The Lancet Public Health, 2020.

Arbyn, M., et al. "The European Response to the WHO Call to Eliminate Cervical Cancer as a Public Health Problem." IJC, 2020.

Arbyn, M., et al. "Triage of HPV-Positive Women in Norway Using Cytology, HPV16/18 Genotyping and HPV Persistence." BJC, 2020.

Rezhake, R., et al. "Triage Options to Manage High-Risk Human Papillomavirus-Positive Women: A Population-Based Cross-Sectional Study from Rural China." IJC, 2020.